Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

NCT06475586 · Completed

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication typically used for diabetes, affects the skin symptoms of psoriasis in adults who have both psoriasis and type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 30 people

Who can join Ages 18–70 · all sexes

Timeline Started 2023-05 · est. completion 2024-06

Where 1 site · Bosnia and Herzegovina

What this study is testing ClinicalTrials.gov NCT06475586 ↗

Description as written by the study sponsor.

The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response

Treatments tested

Semaglutide also known as ozempic Drug

0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks

Main thing measured	clinical characteristics of patients with psoriasis
Sponsor	University of Banja Luka
Conditions studied	Psoriasis Vulgaris, Diabetes Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06475586 ↗